Title A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (Substudy U03A)

Clinical Trial Grant

Duke Scholars

Principal Investigator Michael Roger Harrison Medicine, Medical Oncology

Administered By

Duke Cancer Institute

Awarded By

Merck Sharp & Dohme

Start Date

August 30, 2021

End Date

April 5, 2026

Administered By

Duke Cancer Institute

Awarded By

Merck Sharp & Dohme

Start Date

August 30, 2021

End Date

April 5, 2026